ArticleEndocrine2026
The impact of psammoma bodies on long-term prognosis in papillary thyroid carcinoma.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsammoma bodies are characteristic calcified structures of papillary thyroid carcinoma (PTC), but their pathogenesis and prognostic significance remain unclear. This study evaluated their association with clinicopathological features at diagnosis and long-term recurrence in classic PTC.
methodsThis retrospective study analyzed 102 patients with classic-type PTC followed for a minimum five-year period. Patients were stratified according to psammoma body presence or absence in histopathological specimens.
resultsThe cohort included 102 patients (77 female, 25 male) with a mean diagnostic age of 40.4 (± 13.9) years. Psammoma bodies were identified in 66 cases (64.7%). Patients with psammoma bodies were diagnosed at a younger age (p = 0.015). Although psammoma body presence did not differ by gender, the rate of stromal coarse calcification was significantly higher in male patients (36.0%) than in female patients (13.0%) (p = 0.030). On univariable analysis, the prevalence of lymph node metastasis at diagnosis was significantly higher in the psammoma body-positive group (p = 0.001). In multivariable logistic regression analysis, the number of metastatic lymph nodes showed a positive trend toward an association with psammoma body presence, although this did not reach statistical significance (p = 0.078, OR = 1.745, 95% CI: 0.939-3.241). The presence of lymphocytic thyroiditis in non-tumorous thyroid tissue was associated with a reduced incidence of lymph node metastasis (37.1% versus 62.9%). Concerning long-term outcomes, recurrence rates were numerically higher in the psammoma body-positive group without achieving statistical significance (p = 0.532).
conclusionPsammoma body presence was significantly associated with lymph node metastasis at diagnosis in classic PTC; however, this association was not independently confirmed in multivariable analysis. Psammoma bodies may be associated with nodal disease, but their independent clinical significance remains unclear.
Indexed as
Identifiers
42842060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.